The results of our study showed that treatment of MMD knees with CCL21 antibodies altered mRNA expression of Mmps and mitigated post-MMD inflammation as evidenced by a reduction in the expression of Il-6 and a reduction in inflammatory cell recruitment to the joint of MMD operated knees. This evidence concerns the gene CCL21 and multiminicore myopathy.